None listed
Conditions
Interventions
Dietary Supplement : Subjects will be randomized to receive HLJG0701 capsule 1.5g or placebo. Subjects will orally self-adminster HLJG0701 1.5g or placebo twice, 8 capsule per day for 12weeks.
Sponsors
Hwajin
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subject who have decreased CERAD-K(Consortium to Establish a Registry for Alzheimer’s Disease-Korean version) memory score(1.0SD<= and 2.0SD < CERAD-K memory score) comparing to the same age and education group.
Exclusion criteria
Exclusion criteria: - People who are currently suffering from schizophrenia or have a history of schizophrenia - People who have major depressive disorders categorized by DSM-V(The Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition) - People who have poor cognitive function and have Alzheimer’s disease, Parkinson’s disease, or stroke. (The diagnosis of Alzheimer’s disease is based on DSM-V) - People who have taken medications for Alzheimer’s disease or other cognitive function problems within 4 weeks prior to the first visit of the study. The examples of the medications are Antipsycotics, Neurodegenerative Disease Drugs, Nootropics & Neurotonics, and tricyclic antidepressant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the scores of VLT(Verbal learning test) between baseline and after 12 weeks of the treatment;Changes in the scores of NORT(Novel Object Recognition Test) between baseline and after 12 weeks of the treatment;Changes in the scores of Story Recall Test between baseline and after 12 weeks of the treatment;Changes in the scores of Digit span test(Digit span Forward, Digit span Backward) between baseline and after 12 weeks of the treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the scores of Auditory Continuous Performance Test between baseline and after 12 weeks of the treatment;Changes in the scores of PRMQ(Prospective and Retrospective Memory Questionnaire) between baseline and after 6, 12 weeks of the treatment;Changes in the scores of PSS(Perceived stress Scale) between baseline and after 6, 12 weeks of the treatment;Changes in the scores of BDNF(Brain-Derived Neurotrophic Factor) between baseline and after screening(-2~0), 12 weeks of the treatment | — |
Countries
Korea, Republic of
Contacts
Public Contactyeongchul chung
Chonbuk National University Hospital
Outcome results
None listed